Iovance jumps 36% on a $55 million guidance raise that implies $120 million-plus quarters

Iovance Biotherapeutics raised its 2026 revenue forecast to $410 million to $420 million on Tuesday, from $350 million to $370 million, citing U.S. demand for its melanoma cell therapy Amtagvi and the drug Proleukin. The company said in its 8-K filing that the new midpoint is $55 million, or about 15%, above the old one and implies nearly 60% annual growth.

The stock was up $3.95, or 35.9%, at $14.94 shortly before 3 p.m., according to Nasdaq. It traded as high as $15.30, well above its previous 52-week high of $11.165. About 65 million shares had changed hands, around four times the 16 million daily average. Seeking Alpha reported that analysts welcomed the raise and that the stock hit its highest since 2024.

The number behind the raise

A full-year forecast also sets a second-half target. Iovance's second-quarter release reported about $71 million in first-quarter product revenue and a record $99.3 million in the second quarter, so roughly $170 million for the first half.

• At the low end, $410 million leaves about $240 million for the second half, or roughly $120 million a quarter.
• At the high end, $420 million leaves about $250 million, or roughly $125 million a quarter.
• Against Q2's $99.3 million, the company needs each remaining quarter to run about 21% to 26% higher.

Revenue grew 39% from the first quarter to the second, so the new range does not require the growth rate to speed up. It does require it to hold. Interim CEO Frederick Vogt said "increasing patient demand and our current manufacturing schedule provide strong visibility" into third- and fourth-quarter revenue. For a therapy made from each patient's own cells, with a manufacturing turnaround the company puts at 31 days or less, the treatment schedule gives some view of the next few months.

How the market priced it

Nasdaq put Iovance's market value at about $6.78 billion at $14.94 a share. By that count, Tuesday's move added roughly $1.8 billion in value on a $55 million increase to the revenue forecast, about $33 of market value per dollar of added guidance. Investors are paying for the rate of growth, not only for this year's sales. At the $415 million midpoint, the stock trades at about 16 times this year's expected revenue.

The move also leaves the stock ahead of the analysts. The consensus one-year price target on Nasdaq's summary page was $10, below Tuesday's price.

The bear case, stated fairly

• Guidance is revenue, not profit. The company says it is moving toward profitability but has not reached it. Q2 gross margin was 56%.
• Amtagvi drives almost all of it: about $91 million of Q2's $99.3 million.
• Growth depends on expanding treatment centers, from about 100 now to at least 110 by year-end, and on trials in lung cancer, sarcoma and endometrial cancer that have not yet produced approvals.

What we are watching

Third-quarter results, which Iovance expects in early November. The number to check is whether Q3 revenue lands near the $120 million pace the full-year range implies. Company filings are on SEC EDGAR.

Sources: Iovance Biotherapeutics 8-K filings of Sept. 29 and Aug. 6, 2026; Nasdaq market data (intraday, may be delayed); Seeking Alpha. This is market information, not investment advice.